Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.

[1]  G. Botti,et al.  Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study , 2013, Journal of Translational Medicine.

[2]  G. Sonpavde,et al.  Penile cancer: current therapy and future directions. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[4]  M. Carducci,et al.  Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. , 2012, The oncologist.

[5]  G. Sonpavde,et al.  Cisplatin and 5‐fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis , 2012, BJU international.

[6]  O. Hakenberg,et al.  514 P16INK4a is a marker of good prognosis in primary invasive penile squamous cell carcinoma: A multi-institutional study , 2012 .

[7]  A. Erbersdobler,et al.  Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis , 2011, Journal of Clinical Pathology.

[8]  M. Colecchia,et al.  Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Necchi,et al.  Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Thall,et al.  Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Hoffman-Censits,et al.  Chemotherapy for penile and urethral carcinoma. , 2010, The Urologic clinics of North America.

[12]  I. Tannock,et al.  The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. , 2010, European journal of cancer.

[13]  N. Nicolai,et al.  Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. , 2009, European urology.

[14]  K. O'Byrne,et al.  Cisplatin and gemcitabine in the management of metastatic penile cancer. , 2009, Urologic oncology.

[15]  F. Saad,et al.  A Simple and Accurate Model for Prediction of Cancer-Specific Mortality in Patients Treated with Surgery for Primary Penile Squamous Cell Carcinoma , 2009, Clinical Cancer Research.

[16]  L. Collette,et al.  A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Horenblas,et al.  Neoadjuvant chemotherapy in advanced penile carcinoma. , 2007, European urology.

[18]  P. Spiess,et al.  Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. , 2007, The Journal of urology.

[19]  M. Wirth,et al.  Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma , 2006, BJU international.

[20]  M. Kattan,et al.  Nomogram predictive of cancer specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. , 2006, The Journal of urology.

[21]  M. Kattan,et al.  Nomogram predictive of pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the penis. , 2006, The Journal of urology.

[22]  A. Lopes,et al.  Human papillomavirus as a prognostic factor in carcinoma of the penis , 2001, Cancer.

[23]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Haas,et al.  Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. , 1999, The Journal of urology.

[25]  R. Amato,et al.  Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. , 1998, The Journal of urology.

[26]  S. Fosså,et al.  Cisplatin and 5-fluorouracil in advanced cancer of the penis. , 1992, The Journal of urology.

[27]  C. Logothetis,et al.  Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. , 1991, The Journal of urology.

[28]  A. Erbersdobler,et al.  p16(INK4a) is a marker of good prognosis for primary invasive penile squamous cell carcinoma: a multi-institutional study. , 2012, The Journal of urology.

[29]  C. Coltman,et al.  cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. , 1989, The Journal of urology.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  L. Piva,et al.  Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. , 1988, Acta oncologica.